---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-099382"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:40:31.747583+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alkermes Q2 revenue $390.7M, GAAP EPS $0.52; product sales grow 14% YoY

## Summary
- Total Q2 revenues $390.7M (-2% YoY); GAAP net income $87.1M, diluted EPS $0.52.
- Proprietary net sales $307.2M (+14% YoY): LYBALVI $84.3M (+18%), ARISTADA $101.3M (+18%), VIVITROL $121.7M (+9%).
- Adjusted EBITDA $126.5M; cash & investments $1.05B at June 30, 2025.
- Company reaffirms 2025 financial expectations.
- R&D spend $77.4M (+30% YoY) on alixorexton; positive Vibrance-1 phase 2 results support global phase 3.

## SEC filing metadata
- accession: 0000950170-25-099382
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000095017025099382/0000950170-25-099382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000095017025099382/alks-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-099382
- JSON: https://secwatch.observer/filing/0000950170-25-099382.json
- Plain text: https://secwatch.observer/filing/0000950170-25-099382.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.